Autonomic Technologies, Inc.: Series A $5.0M

Autonomic Technologies (Menlo Park, CA) makers of neuromdoulation stimulation devices closed on the first $3M traunche of a $5M Series A financing. Participants in the round include Kleiner Perkins Caufield & Byers and the Cleveland Clinic.

ProFibrix B.V.: Series A €8.5M

ProFibrix (Netherlands) a biotech company focused on fibrinogen-based products to stop surgical hemmoraging and initiate tissue repair, has closed a €8.5M Series A round. The deal was led by Index Ventures.

Numira Biosciences, Inc.: Series A $2.5M

Numira Biosciences (Irvine, CA) a medical device company specializing in high resolution bone imaging and virtual histology has raised a $2.5M Series A round. The deal was led by vSpring Capital and joined by Tech Coast Angels and Pasadena Angels.

Affinium Pharma, Inc.: Series A $18M

Affinium Pharmaceuticals (Canada) who is developing a new class of antibiotics targeting staph infections closed an $18M Series A financing. The deal was lead by Forward Ventures along with Oxford Bioscience , SV Life Sciences and Genesys Capital Partners.

Okairos AG: Series A €7.2M

Okairos (Switzerland) a biopharmaceutical company using adenovirus-based technology to focus on T-cell vaccines has closed a €7.2M Series A financing. The deal was led by Life Science Partners and Biomedinvest and was joined by the Novartis Venture Fund.

Tragara Pharma, Inc.: Series A $40M

Tragara (San Diego, CA) a pharmaceutical company developing therapies for the treatment of lung cancer and inflammatory diseases closed a $40M Series A round. The financing was led by Domain Associates, ProQuest Investments, Morgenthaler Ventures, Oxford Bioscience Partners and Mitsubishi International Corporation.

Epiphany Biosciences, Inc.: Series A $36M

Epiphany Biosciences (San Francisco, CA) is developing both therapeutic products and diagnostic technologies that treat or prevent the spread of pathogenic viruses a new with its lead product for the treatment of Shingles closed a $36M Series A. The round was led by Wexford Capital other participants included Windsor Bay Capital, Global Trust Ventures Management and CDIB BioScience Venture Management.

VentiRx Pharma, Inc.: Series A $26.6M

VentiRx Pharmaceuticals (Seattle, WA) a biopharmaceutical company focused on the development of medicines for the treatment of cancer and infectious, respiratory and autoimmune diseases, raised a $26.6M Series A round. The deal was led by Frazier Healthcare Ventures, ARCH Venture Partners and Domain Associates.

Trius Therapeutics, Inc.: Series A $20M

Tirus Therapeutics (San Diego, CA) a biopharmaceutical company developing next generation antibacterial drugs closed a $20M Series A round. The deal was led by Sofinnova Ventures and joined by InterWest Partners, Prism VentureWorks and Versant Ventures.

Calistoga Pharma, Inc.: Series A $21M

Calistoga Pharmaceuticals (Seattle, WA) a drug development startup focused on oncology and inflammation raised a $21M Series A. The deal was led by Frazier Healthcare Ventures and was joined by Alta Partners, Three Arch Partners and Amgen Ventures.